Physician Views: Gauging oncologists reaction to ASCOs new tool for rating cancer drugs

Physician Views: Gauging oncologists reaction to ASCOs new tool for rating cancer drugs

Code: FW-20150606 | Published: Jun-2015 | Pages: - | FirstWord
Price :
$695.00
USD

* Required Fields

$695.00

Details






The rising price of cancer drugs in the US has drawn plenty of criticism, and can be particularly frustrating for physicians and patients given the lack of transparency about how much bang they are getting for their buck.

A taskforce of clinicians convened by the American Society of Clinical Oncology (ASCO) last week published the details of a "value framework" for scoring cancer drugs based on their benefit/risk profiles, which will be made available alongside each drugs price to allow physicians and patients to have a more open discussion about how to proceed with treatment. (See ViewPoints: ASCOs new tool for rating cancer drugs is a much-needed first step towards bending the cost curve.)

Specifically, the framework uses the results from clinical trials of a drug to assign it a "net health benefit" score based on the level of efficacy and side effects that were observed. Medicines offering more benefit and/or less toxicity receive higher scores than drugs with less benefit and/or more toxicity. The maximum score for drugs in the adjuvant setting is 100, while the scale used for those treating metastatic disease goes up to 130, including 30 "bonus" points for improving symptoms or quality of life.

Clifford Hudis, a medical oncologist at Memorial Sloan Kettering Cancer Center and a co-author of the paper describing the framework, told FirstWord PLUS that the taskforce hopes it will eventually evolve into an easy-to-use tool to compare the value of different drugs in specific tumour types. However, he also acknowledged that the initial framework will require plenty of refining, meaning last weeks version is intended to elicit feedback from stakeholders.

One notable aspect of the framework is what it does not do in that it stops short of combining the "net health benefit" and cost, which is a logical next step that organisations like the National Institute for Health and Care Excellence (NICE) in the UK have in fact taken and use to measure a drugs cost effectiveness, with those deemed not to be cost effective not being eligible for reimbursement.








To gain better understanding about physicians feelings on ASCOs newly released framework, FirstWord PLUS is polling US-based oncologists and asking them


- How often do you to take the cost of a cancer drug into consideration when making a recommendation on a patients course of treatment?
- This week, ASCO proposed a framework for assigning a cancer drug a score based on its risk/benefit profile, which clinicians can use along with the drugs price to help inform treatment decisions. The physicians who came up with it noted that it is a draft proposal that needs refining. How likely are you to use the limited information from the preliminary framework to help guide your discussions with cancer patients?
- How confident are you that ASCOs preliminary framework will eventually evolve into a standardised tool that can be used in the real world to help guide cancer treatment?
- What represents the biggest challenge in developing a standardised tool that can be used in the real world to help guide cancer treatment?
- ASCOs preliminary framework stops short of incorporating the cost of a drug into the final score it is assigned. Would you prefer that cost be included in the final score?



Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord

Our Clients